TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential.
Amicus Therapeutics Inc. (FOLD)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Palo Alto Investors William Leland Edwards | 0 | $0 | 0% | |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% | |
| 3. | Glazer Capital Paul Glazer | 0 | $0 | 0% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 0 | $0 | 0% | |
| 5. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.49 | 1,500 | $15,735.00 | 65,082 | 2021-11-01 | Filing | |
| $9.56 | 1,500 | $14,346.00 | 63,582 | 2021-10-01 | Filing | |
| $11.41 | 1,500 | $17,115.00 | 62,082 | 2021-09-01 | Filing | |
| $9.28 | 1,500 | $13,920.00 | 60,582 | 2021-08-02 | Filing | |
| $9.24 | 1,500 | $13,861.20 | 47,467 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.35 | 22,500 | $322,839.00 | 998,680 | 2026-03-02 | Filing | |
| $14.31 | 75,000 | $1,073,182.50 | 1,021,180 | 2026-01-20 | Filing | |
| $14.17 | 25,642 | $363,380.47 | 245,690 | 2025-12-19 | Filing | |
| $10.86 | 77,926 | $846,011.41 | 1,129,782 | 2025-12-15 | Filing | |
| $11.00 | 25,643 | $282,073.00 | 271,332 | 2025-12-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 796 | $11,534 | 0% | |
| 2. | 1 | $14 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
13 Hot Stocks to Buy with the Highest Upside Potential
In this article, we talk about the 13 hot stocks to buy with the highest upside potential.
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Amicus Therapeutics, Inc. tops our list for being one of the best biotech stocks.
20 Best Biotech Stocks Under $20 to Buy Now
In this article, we will be taking a look at the 20 Best Biotech Stocks Under $20 to Buy Now. The U.S.
Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger
We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday.
Amicus Therapeutics (FOLD) Soars to 52-Week High on 'Strong Buy' Reco
We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday.
Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results
With significant upside potential and hedge fund interest, Amicus Therapeutics, Inc. (NASDAQ:FOLD) secured a spot on our list of the 15 stocks set to explode in 2026.
15 Stocks Set to Explode in 2026
In this article, we discuss the 15 stocks set to explode in 2026.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2025 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2025 Earnings Call Transcript November 4, 2025Amicus Therapeutics, Inc. misses on earnings expectations. Reported EPS is $0.06 EPS, expectations were $0.12.
What Does Wall Street Think About Amicus Therapeutics (FOLD)?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc.